90 related articles for article (PubMed ID: 16679946)
1. Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload.
Nelson SC; Hennessy JM; McDonough EA; Guck KL
J Pediatr Hematol Oncol; 2006 Mar; 28(3):182-5. PubMed ID: 16679946
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR
Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690
[TBL] [Abstract][Full Text] [Related]
3. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
Wali YA; Taqi A; Deghaidi A
Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
[TBL] [Abstract][Full Text] [Related]
4. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
Lombardo T; Ferro G; Frontini V; Percolla S
Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
[TBL] [Abstract][Full Text] [Related]
6. Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine.
Surapolchai P; Poachanukoon O; Satayasai W; Silapamongkonkul P
J Med Assoc Thai; 2014 Aug; 97 Suppl 8():S217-22. PubMed ID: 25518318
[TBL] [Abstract][Full Text] [Related]
7. Intravenous chelation therapy during transplantation for thalassemia.
Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
[TBL] [Abstract][Full Text] [Related]
8. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion.
Yarali N; Fişgin T; Duru F; Kara A; Ecin N; Fitoz S; Erden I
J Pediatr Hematol Oncol; 2006 Jan; 28(1):11-6. PubMed ID: 16394886
[TBL] [Abstract][Full Text] [Related]
10. [Retinal pigment epithelium--desferal].
Roulez F
Bull Soc Belge Ophtalmol; 2007; (304):59-66. PubMed ID: 17718228
[TBL] [Abstract][Full Text] [Related]
11. [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)].
Lévy G; Bachelot C; Joannard A; Bost M
Arch Fr Pediatr; 1980 May; 37(5):299-303. PubMed ID: 7469704
[TBL] [Abstract][Full Text] [Related]
12. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
Baath JS; Lam WC; Kirby M; Chun A
Retina; 2008 Jun; 28(6):894-9. PubMed ID: 18536609
[TBL] [Abstract][Full Text] [Related]
13. Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
Badat M; Kaya B; Telfer P
Br J Haematol; 2015 Nov; 171(3):430-2. PubMed ID: 25855051
[No Abstract] [Full Text] [Related]
14. Long-term intraperitoneal deferoxamine for hemochromatosis.
Swartz RD; Legault DJ
Am J Med; 1996 Mar; 100(3):308-12. PubMed ID: 8629676
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy.
Sheth S; Ruzal-Shapiro C; Hurlet-Jensen A; Piomelli S; Berdon WE
Pediatr Radiol; 1997 Dec; 27(12):926-8. PubMed ID: 9388284
[TBL] [Abstract][Full Text] [Related]
16. Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran.
Rashid M; Karimi M
Transfus Med; 2012 Apr; 22(2):104-7. PubMed ID: 22212011
[TBL] [Abstract][Full Text] [Related]
17. Management of iron overload with a disposable multi-day delivery system.
Paolo C; Francesco S; Sergio A
Am J Hematol; 1996 Jan; 51(1):95. PubMed ID: 8571948
[No Abstract] [Full Text] [Related]
18. [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
Kobayashi M; Yano K; Fujisawa S
Rinsho Ketsueki; 1996 Apr; 37(4):303-10. PubMed ID: 8847800
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and therapeutic challenges.
Reddy S; Slakter J; Aaberg TM; Singh RP; Kaiser PK
Retina; 2007 Jun; 27(5):642-7. PubMed ID: 17558329
[No Abstract] [Full Text] [Related]
20. Intensification of chelating-therapy in patients with thalassemia major.
Laws HJ; Göbel U; Christaras A; Janssen G
Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
